Consistently, we observed that CBLC downregulation phenocopied the anti-oncogenic effects of the R427 mutation in DU145 cells, establishing for the first time that CBLC exerts tumor promoting activities in prostate cancer cells. Here, CBLC is linked to prostate carcinoma.